Company intelligence / Profile preview
Denovo Biopharma
San Diego, California, USAdenovobiopharma.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 3
01
Overview
Denovo Biopharma has achieved a major breakthrough in treatment-resistant depression with its biomarker-guided Phase 2b trial of DB104 (liafensine), meeting all major endpoints. The company’s lead oncology program DB102 (enzastaurin) has reached pivotal Phase 3 trials for DLBCL and GBM. Its pipeline includes eight late-stage drugs addressing unmet needs in oncology and CNS diseases.
- Therapeutic areas
- OncologyNeurology
- Modalities
- small moleculesgene therapy-based drugsrecombinant proteins/large molecules
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Aytu BioPharma for DB102 development/licensing for rare genetic diseases such as vascular Ehlers-Danlos syndromeJiangsu Wuzhong Pharmaceutical Group for endostatin rights acquisition outside China
Beyond the preview
Go deeper on Denovo Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Denovo Biopharma.